NCT07642544Not yet recruiting
Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis
Effects of Different Secukinumab Maintenance Regimens on Long-Term Outcomes in Patients With Psoriasis: A Single-Center Real-World Cross-Sectional Retrospective Study
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
To evaluate the long-term efficacy of two maintenance treatment patterns of secukinumab-the standard maintenance group and the non-standard maintenance group-by assessing the median time to onset and incidence of secondary failure, as well as the time to regain response after dose escalation of secukinumab (including re-initiation of intensive dosing or shortening of the injection interval) in patients who experienced secondary failure.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 22 May 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Diseases
- Psoriasis
- NCT number
- NCT07642544
What you commit to
- Study type: Observational
- Planned participants: 120
- From 1 Jun 2026 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of other targeted biologic agents or small molecule drugs during the maintenance period.
Other illness
- Failure to complete the induction period, or failure to achieve PASI 75 response by the end of the induction period.
- Permanent discontinuation of treatment for non-efficacy reasons, such as pregnancy, severe infection, or malignancy.
Other
- Irregular maintenance treatment pattern, or substantial missing data.
- Participation in other interventional clinical trials that may confound efficacy assessment.
Who the study is looking for
- Age ≥ 18 years, with a clinical diagnosis of moderate-to-severe plaque psoriasis.
- Initiated secukinumab treatment at our center between January 2020 and December 2025, and completed the standard 5-week induction period.
- Achieved PASI 75 response at the end of the induction period.
- Had a clearly defined maintenance treatment pattern (standard or non-standard), with complete treatment records and regular efficacy assessments.
- Complete electronic medical record data available for extraction.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medicine School Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.